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Purpose: True abscopal responses from radiation therapy are extremely rare; the
combination of immune checkpoint inhibitors with radiation therapy has led to more
reports of the abscopal effect, but even in this setting, the genuine magnitude remains
unknown and is still considered generally uncommon. We report the occurrence of
what appears to be putative, durable abscopal tumor responses with associated
auto-immune systemic reactions resulting from the combination of local radiotherapy
(RT) and modulated electrohyperthermia (mEHT).
Materials and Methods: Data from advanced cancer patients treated palliatively
with RT and mEHT between January and December 2017 were collected as part of
a post-marketing safety monitoring program of mEHT therapy. We specified a minimum
RT dose of 30Gy and at least four mEHT treatments for reporting toxicities, which was
the primary aim of the larger study.
Results: Thirty-three patients treated with RT and mEHT, both applied to the same
lesion, were included. The median RT dose was 45.5Gy in 20 fractions (fxs) and
the median number of mEHT treatments was 12 (range, 4–20). Most patients had
subsequent systemic therapy after one course of RT and mEHT. Three patients (9.1%)
developed autoimmune toxicities. Case number 1 received RT and mEHT only; case
number 2 had two cycles of concurrent low dose chemotherapy during RT; and case
number 3 received concurrent immune checkpoint inhibitors. None of the three patients
received any further systemic treatment due to obvious treatment-related autoimmune
reactions which occurred rapidly after RT; one had autoimmune hepatitis, one had
dermatitis herpetiformis and the third developed severe myasthenia gravis. Interestingly,
what we surmise to be long-lasting abscopal responses outside the irradiated area, were
noted in all three patients.
Conclusion: RT combined with mEHT could putatively result in enhancing immune
responsiveness. These preliminary observational findings lead to the generation of a
hypothesis that this combination induces both an in-situ, tumor-specific immune reaction
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and an anti-self-autoimmune reaction, in at least a small proportion of patients, and of
those who experience the auto-immune response, tumor response is a concomitant
finding. Mechanisms underlying this phenomenon need to be investigated further.
Keywords: modulated electrohyperthermia, immunotherapy, radiotherapy, abscopal effect, immune-related
adverse events
INTRODUCTION
Local hyperthermia (HT) has long been regarded as an effective
radio-sensitizer (1). Modulated electrohyperthermia (mEHT)
therapy is one form of hyperthermia (2). mEHT utilizes the
biophysical differences between malignant and normal cells
for cancer-cell specific selective energy deposition, believed to
be due to the lower impedance on the transmembrane protein
clusters of malignant cells (3). The modulated electromagnetic
frequency spectrum of 13.56 MHz from mEHT is similar to
the alternating electrical field generated from tumor treating
field therapy (TTField, Novocure, Inc.) (4–6). mEHT applies
lower power than conventional HT, thus interstitially measured
average temperature is relatively low, around 39.5◦C. However,
the corresponding transmembrane temperature differential
across a cell is often quiet high (7). This transmembrane
thermal stress destabilizes cell membranes, resulting in necrosis,
and also enhanced apoptosis (8–11). This effect has been
shown to enhance the release of heat shock proteins (HSPs),
produce damage-associated molecular patterns (DAMP)
and leads to increased immunogenicity, thereby mediating
immunogenic cell-death (12). The electric field effect has
also been demonstrated to activate intensive lymphocytic and
dendritic cell penetration into tumor (13).
The abscopal effect from radiotherapy (RT) has been known
for a long time and was interpreted as an immune-mediated
effect (14). Despite millions of patients having been treated with
RT, only 46 abscopal cases induced by radiation treatment alone
have been described between 1969 and 2014 (15). In preclinical
models, the combination of immune check point (ICP) inhibitors
with RT has demonstrated abscopal effects, but human reports
still remain sparse, largely restricted to melanoma and non-
small cell lung cancer (16–21). However, in all such reports,
it remains difficult to ascribe the abscopal effect purely to RT
alone or in combination with immune enhancing therapeutics
(22). A prospective trial of RT, with a granulocyte-macrophage
colony stimulating factor in metastatic diseases, reported a
surprisingly high abscopal effect of 27.6% (23). RT creates tumor
and normal tissue damage, lysis, and antigen release for sustained
in-vivo vaccination events. Thymus-derived regulatory T (Treg)
cells played a critical role in the control of immune tolerance
to self-antigens, however, they also resulted in reduced anti-
tumor immunity (24). There were very few literature reports
on how therapy related autoimmunity-mediated antitumor
activity (25, 26).
We speculated that the incidence of the abscopal effect may
be higher in patients who develop autoimmunity. Bakacs et al.
reported that immune related adverse events (irAEs) induced
by ipilimumab are very similar to the chronic graft vs. host
disease that ensues allogenic bone marrow transplantation (27).
Autoreactive T cells may bypass the negative selection pressure
in the microenvironment of the tumor and differentiate to
memory T cells that recognize both “self ” and “tumor.” We
report, we believe for first time, that patients treated with RT and
mEHT may have a long treatment-free period once they unleash
an autoimmune reaction, and further, that in such patients,
successful salvaging through low-dose ICP inhibitors may be
possible at tumor recurrence.
MATERIALS AND METHODS
We performed a single institution, observational case-cohort
study for patients with metastatic cancers of various origins,
treated with a combination of RT and mEHT, with a minimum
RT dose of 30Gy and at least four mEHT treatments, to
report unexpected adverse events. This retrospective analysis
was conducted as part of a post-marketing safety surveillance
program after the approval of the mEHT device in the class
III medical category in Taiwan. The study was approved by the
Institutional Review Board and was conducted according to the
guidelines of Good Clinical Practice.
Patient Selection
Enrolled patients were 20 years of age or older, presented with
inoperable, recurrent, or metastatic diseases, requiring palliation
with RT. In our study, all patients underwent concurrent RT
and mEHT with or without systemic therapies, based on the
underlying clinical condition. All institution-specific consent
requirements were adhered to; written informed consent was
obtained from the participants for the publication of the
case series.
Radiotherapy
RT was performed using conventional fractionation (and not
hypofractionated) schedules, with a dose of 2 to 3.5Gy per
fraction (fx), five times per week to at least 30Gy, as clinically
appropriate and necessary. The clinical target volume (CTV)
was defined as the gross tumor volume (GTV) plus a margin
of 3–5mm, based on the specific tumor type being addressed.
Patients were treated with Elekta Synergy R© (Elekta, Stockholm,
Sweden) or TomoTherapy R© (Accuray, Sunnyvale, CA, USA)
with standard immobilization devices, using image-guided,
modulated arc therapy with 6-MV photons for most of the
patients. For patients who had received RT prior to the study, the
original treatment plans were retrieved in every case of suspected
overlap with the prior RT fields, and appropriate organ-at-risk
constraints were adhered to.
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Hyperthermia (mEHT)
The mEHT treatment was applied using an EHY 2000+
hyperthermia device (OncoThermGmbH, Germany). Treatment
lasted for 60min and was administered once weekly. A 30 cm in
diameter circular electrode was placed at the irradiated tumor
site, approximating placement at the radiation field isocenter.
A 13.56 MHz radiofrequency (RF) was used with a real-time,
automatic tuning device resulting in energy-transfer matching
and ensuring a standard wave ratio of ∼1 (the most ideal value).
The power was initially set to 80 Watts (W) and a step-up
protocol was applied to increase by 20–30W every 5min, until
150W was reached for the remaining treatment duration. The
goal for the target energy delivered was minimally set at 500 kJ
per treatment. All appropriate vital sign monitoring during and
after treatment was conducted as per standard practice. With this
technique, intratumoral temperature measurement is typically
not performed because the temperature elevation measured by a
conventional thermocouple is usually <2◦C (28). Adverse events
were assessed throughout each treatment, which included heat
sensitivity, skin burning, pain, and gastric discomfort.
Outcomes Evaluation
The primary endpoint was toxicity, which was evaluated weekly
and recorded using the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0. during the RT and mEHT
period and 2 months after. The secondary outcome was the
radiologic response, which was evaluated on the irradiated
lesions according to the Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 (29) every 3 months with CT,
PET-CT, or tumor markers, based on a baseline selection
diagnostic/imaging finding. The response categories of interest
included complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD). Most patients
received some kind of systemic treatment afterward. The length
of follow-up was defined from the last day of RT to the last follow-
up visit. Baseline measurements and changes in the neutrophil to
lymphocyte ratio (N/L) before and after treatment were collected.
Statistical Analysis
The impact of patient-, tumor-, and treatment-related factors
on response was evaluated using a univariate and multivariable
analysis. Survival curves were estimated using the Kaplan-
Meier method. Fisher’s exact test (two-tailed test) was used
for evaluating 2 × 2 tables for significance. Statistical analyses
were performed with the SAS statistical software (version
9.2; SAS Institute, Cary, NC, USA). P < 0.05 were set for
statistical significance.
RESULTS
Patient and Disease Characteristics
Thirty-three patients with recurrent or metastatic cancer was
enrolled between January 2017 and December 2017. Patient
characteristics are listed in Table 1. The median patient age
was 59.3 years (range, 38–84 years). Breast cancer, lung cancer,
hepatoma, cholangiocarcinoma, and urothelial carcinoma were
the five most common disease entities. The thorax was the most





Age, median, range, years 59.4 38–84 years-old
Disease entities
Breast cancer 8 24.4
Lung cancer 4 12.1
Hepatocellular carcinoma 3 9
Cholangiocarcinoma 3 9
Urothelial carcinoma 3 9
Others 12 36.5
Treatment before RT+ mEHT
Surgery 12 36.3
RT 19 57.6
ChT (include hormone, target therapy) 21 63.6
IO 0 0
Cht+IO 2 6
Treatment during RT+ mEHT
ChT (include hormone, target therapy) 16 48.5
IO 9 27.2
ChT+IO 6 18.2
Treatment after RT+ mEHT
Surgery 1 4.6
ChT (include hormone, target therapy) 13 59.1
IO 3 13.6
ChT+IO 5 22.7
Cht, chemotherapy; IO, immune-Oncology.
commonly treated site (12 patients in total, including four lung
cancer patients and eight for breast cancer) followed by abdomen
(nine patients) and liver (six patients). During the RT and mEHT
treatment, 16 patients received concurrent chemotherapy, nine
had ICP inhibitors and six were treated with both agents. The
median follow-up time was 11.6 months (range, 4–22.7 months)
with no patients lost for follow-up.
Treatment
The median RT dose was 45.5Gy (range, 30–66Gy), and the
mean GTV was 138.9 cm3 (ranged between 20 and 5064.7
cm3). The median number of mEHT treatment fractions was 12
(range, 4–20).
Treatment Outcome and Toxicities
The combination of RT and mEHT treatment was well-tolerated.
A full listing of adverse events during the RT plus mEHT
treatment is provided in Table 2. Common treatment-related
adverse events were grade 1 skin, and grade 2 myelotoxicities.
Transient core body temperature elevation (>38◦C), which
resolved shortly after mEHT treatment, was noted in six patients;
two obese patients had localized subcutaneous fat induration
that persisted for several weeks, and then resolved. The most
important adverse events that went beyond our expectation were
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TABLE 2 | Treatment toxicities during RT + mEHT.
Treatment toxicity (CTCAE v4.0)
Toxicity Case number (N) %
Skin toxicity
Grade 0 20 60.6
Grade 1 12 36.3
Grade 2 1* 3.1
Grade 3 0 0
Hepatic toxicity
Grade 0 31 93.8
Grade 1 1 3.1
Grade 2 0 0
Grade 3 1** 3.1
Myelotoxicity
Grade 0 24 72.7
Grade 1 1 3.1
Grade 2 6 18.2
Grade 3 2 6.0
Neurotoxicity
Grade 0 32 96.6
Grade 1 0 0
Grade 2 0 0
Grade 3 1*** 3.1
Nausea and vomiting
Grade 0 30 90.9
Grade 1 1 3.1
Grade 2 2 6.0
Grade 3 0 0
Diarrhea
Grade 0 30 90.9
Grade 1 1 3.1
Grade 2 2 6.0
Grade 3 0 0






*Autoimmune reaction: Dermatitis herpetiformis.
**Autoimmune reaction: Autoimmune hepatitis.
***Autoimmune reaction: Myasthenia gravis.
autoimmune related toxicities (three out of 33 patients, 9.1%).
One patient treated only with RT and mEHT developed grade
3 autoimmune hepatitis. One patient who was simultaneously
treated with low-dose ICP (Yervoy R© and Opdivo R©) developed
grade 3 myasthenia gravis, and another patient developed grade
2 autoimmune-related skin toxicity (dermatitis herpetiformis).
All three patients who developed autoimmune toxicities had long
lasting abscopal effects in the absence of any further subsequent
systemic treatment.
Among the in-field evaluable lesions treated with RT and
mEHT (39 lesions in 33 patients), CR, PR, SD, and PD were
observed in 6.1, 54.5, 27.3, and 12.1% of patients (Table 3).
All eight breast cancer patients had ≧PR response. Somewhat
surprisingly, larger tumors (>500ml) demonstrated superior
responses than smaller tumors (<500ml) (100 vs. 48%, p =
0.012) (Table 3). All the patients with autoimmune toxicities
had a tumor size of more than 500ml. Because of the small
sample size, multivariate analysis failed to show significant
differences between response and age, tumor size, number of
mEHT treatments, tumor depth, the use of ICP inhibitors,
chemotherapy, and autoimmune reactions. Thirteen patients
(39.4%) had a decreased N/L ratio 1 month after RT + mEHT,
which includes two patients with CR, six with PR, three with
SD and two with PD (Table 3). The three patients with an
autoimmune abscopal effect had an elevated N/L ratio before
treatment (>8) which decreased to <3.5 after treatment. The
median survival time was 11.4 months (range, 2.6–16.9 months)
in patients whose N/L decreased, vs. 8.9 months in patients with
elevated N/L (range, 1.7–16.2 months).
Case Presentation: Autoimmune
Phenomena Associated With Abscopal
Tumor Response
Case 1
A 42-year-old female patient presented with a left breast
ulcerative fungating mass (>10 cm) with palpable bilateral
axillary lymph nodes. She was diagnosed with metastatic, left
breast, triple-negative invasive ductal carcinoma. She refused
chemotherapy and received palliative RT consisting of 50Gy
in 25 fxs plus weekly mEHT for six treatments. Elevated
serum alanine and aspartate aminotransferases (ALT and AST),
alkaline phosphatase and bilirubin was identified 2 weeks after
RT. Positive anti-microsomal antibody and anti-smooth muscle
antibody levels assisted in making a diagnosis of autoimmune
hepatitis. She was treated with prednisone (starting at 40mg
daily and tapered to 10mg daily within 4 weeks). The primary
tumor shrank rapidly to ∼1 cm 1 month after treatment and
a wide excision was performed 2 months later (Figure 1A).
The bilateral axillary and the left internal mammary metastatic
lymph nodes outside the local treatment field demonstrated
dramatic and sustained regression, qualifying for our abscopal
response criteria. More than 1 year later, she developed lung
metastases and was treated bi-weekly with reduced-dose ICP
inhibitor treatment (60mg of Opdivo R©) for two doses with a
significant response (Figure 1B), resulting in a CR. Subsequently,
her serum AST, ALT, and bilirubin levels increased once again,
suggesting relapse of her autoimmune hepatitis, resulting in
discontinuation of immunotherapy (Figure 1C). Despite this,
her lung metastases demonstrated sustained remission, and she
is still alive and tumor-free, >12 months after discontinuing
ICP therapy.
Case 2
A 60-year-old female had right renal pelvis urothelial carcinoma
diagnosed in October 2016. She underwent robotic right
nephroureterectomy and bladder cuff excision, revealing a
pT4N0 tumor treated with adjuvant tumor bed radiotherapy to
48Gy in 24 fxs (completed in January 2017). In May 2017, she
presented with a rapidly growing, painful, palpable abdominal
mass. An abdominal CT scan showed multiple intra-abdominal
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Decreased N/L ratio post
treatment (N = 13)****
Increased N/L ratio post
treatment (N = 20)
CR 2 (6.1%)
8*** (100%) 12 (48%)
2 0
VGPR* 5 (15.2%) 3 2
PR 13 (39.4%) 3 10
SD 9 (27.3%)
0 (0%) 13 (52%)
3 6
PD 4 (12.1%) 2 2
*VGPR, Very good partial response defined as >90% regression.
**p = 0.012 Fisher’s exact test.
***The 8 patients with large tumors included 3 patients with autoimmune toxicities including 1 CR (urothelial carcinoma); 1 VGPR (breast cancer), 1 PR (cholangiocarcinoma). Another
5 patients included 1VGPR (hepatoma) and 4 PR (1 cervix and 3 breast cancers).
****p = 0.245 Fisher’s exact test.
FIGURE 1 | Representative patient (Case 1) with autoimmune mediated
abscopal effects. (A) Locally advanced breast cancer with tumor abscopal
effect on bilateral axillary and internal mammary lymph nodes. (B) Progressive
lung metastatic lesions successfully salvaged with 2 cycles of low dose
Opdivo®. (C) Flare up of autoimmune hepatitis by RT plus mEHT and ICP
inhibitors.
masses and a right retroperitoneal mass attached to the right
psoas muscle. The largest tumor was 4.5 cm. There was also a
separate lower anterior abdominal wall mass and a liver segment
7 metastases. She received a second course of palliative RT
targeting the symptomatic and dominant right lower quadrant
mass and the lower abdominal wall mass, both treated to 40Gy
in 20 fxs, along with five weekly mEHT treatments. Concomitant
carboplatin at 300mg and gemcitabine at 600mg were given for
only two cycles and discontinued after pancytopenia developed.
The abdominal pain resolved quickly, and she developed a mild
fever with elevated CRP and pancytopenia in the 3rd week of
treatment. A generalized itchy skin rash developed over the trunk
in the 4th week of treatment. She was diagnosed with dermatitis
herpetiformis and macrocytic anemia with positive anti-parietal
cell antibody. The skin lesions were controlled with low-dose
prednisolone (10mg, once daily). A CT scan in August 2017
showed CR at the irradiated sites. Unexpectedly, an abscopal
effect of the hepatic metastases was also identified (Figure 2)
which was unlikely to be from the systemic effect of only two
cycles of low doses of carboplatin and gemcitabine. No further
treatment was administered. A recent follow-up CT scan in May
2019, 2 years after palliative RT, showed persistent CR of all
disease sites.
Case 3
This 69-year-old male patient had a biopsy-proven
cholangiocarcinoma with multiple metastases diagnosed
in August 2017. He began treatment with immunotherapy
(Yervoy R© at 50mg for one dose only and Opdivo R© at 60mg
every 2 weeks) for eight cycles, RT (45Gy in 15 fxs to the liver,
30Gy in 10 fxs to the scapula, L1 spine, and right pelvic bone),
and weekly mEHT for 12 sessions starting from September
2017. In December 2017, he suffered from progressive muscle
weakness with mild ptosis, lethargy, and difficulty in swallowing.
He developed an aspiration pneumonia, requiring intubation
and supportive management in the neurology intensive
care unit. A positive acetylcholine receptor (AchR) antibody
with electromyogram findings confirmed a new diagnosis of
myasthenia gravis (MG). The patient gradually recovered after
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FIGURE 2 | Representative patient (Case 2) with autoimmune mediated
abscopal effects: metastatic urothelial carcinoma with abscopal tumor effect
on liver metastases.
receiving plasmapheresis, steroids, and antibiotics. He did not
receive any further anti-neoplastic therapy and was maintained
on prednisolone, 5mg once daily, for the subsequent 10 months.
Follow-up imaging showed good PR at irradiated sites with
measurable PR of the unirradiated L5 spine metastases. The
CA 19-9 level peaked to 555 U/ml in 2018/3 and gradually
dropped to 76.7 U/ml in 2019/6 (Figure 3) and he remained
asymptomatic without any systemic treatment.
DISCUSSION
Although our patients were heterogeneous in terms of
histology, lesion numbers, and prior treatments, in general,
they represented a relatively common pool of patients referred
for palliative radiotherapy, i.e., relatively large, symptomatic
disease, either heavily pretreated or having declined during other
therapies. In that context, the 60.6% overall response rates of the
locally treated (RT plus mEHT) lesions may suggest a synergistic
or radiosensitizing effect. Unexpectedly, tumors larger than
500ml, had an even better response rate. Intriguingly, three cases
of autoimmunity occurred after treatment, which was associated
with abscopal tumor response.
What possible mechanisms could be at play here? The
combination of systemic autoimmune effects and tumor abscopal
effects provoked by combined mEHT and RT from local
treatment leads us to speculate the possibility of the clonal
expansion of a subset of T cells targeting both tumor antigens
and shared normal tissue epitopes. These patients required
steroids for managing their autoimmune reactions, without loss
of tumor control. mEHT induces tumor cytotoxicity through a
combination of localized thermal effects, and the temperature
independent signal-excitation effect for DAMP release (12,
30). HSP-associated DAMP could facilitate immunogenicity,
especially in the context of concomitant RT and possible
combination with immune checkpoint inhibitors. The addition
of ICP inhibitors after concomitant chemoradiotherapy (CCRT)
in stage III lung cancer patients, improves both progression-
free and overall survival rates relative to any other consolidative
approach, suggesting the possibility that localized therapy creates
a milieu for ICPs to have more durable effects (31, 32).
Are the local and abscopal responses reported herein,
especially their depth and durability, expected and routine?
Patients in this study were generally at such an advanced stage
of their disease, that first, the expected response rates would be
rather low, and second, durability would be very uncommon.
This leads us to hypothesize that our clinical observations would
require the development of unleashed anti-tumor autoimmunity,
possibly from combinatorial mEHT and RT. In the three cases
with autoimmune toxicity, Case 1 was treated with RT and
mEHT only; Case 2 received only two cycles of reduced dose
concomitant chemotherapy and Case 3 had immunotherapy with
RT. It would be very unlikely that the abscopal liver metastasis
response in Case 2 was a chemotherapy effect. Whether the
remote bony metastases response in Case 3 qualified as a pure
“abscopal effect” is debatable. Nevertheless, the autoimmune
reactions in the three cases after local treatment were quite clear.
Immune response through in-situ vaccinationmight be amplified
by the addition of ICP inhibitors as the third case described
or might yield a deeper response as the second case described.
Gauci et el. recently reported that in order to prolong survival, a
CR or PR within 3 months after treatment was mandatory with
anti-PD-(L)1 monotherapy for multiple cancer types (33).
Larger tumors had better responses to combined RT and
mEHT treatment, which is counterintuitive. Explanations for
this include the possibility that large tumors, especially those
near the body surface under the electrode, absorb more
energy from the RF current (34). For example, in an in vivo
experiment, the use of a large 20mm diameter electrode to
deliver mEHT to 8mm diameter size murine tumors resulted
in impressive apoptosis, necrosis, and extracellular damage-
associated molecular secretion patterns (12, 13), presumably
because the entirety of the tumor was able to absorb energy
effectively. Similarly, all eight breast cancers responded to this
treatment. The radiation fractional dose used in our series is
classic and typical for palliative radiotherapy, but atypical as far as
several preclinical combinatorial immune checkpoint-radiation
experiments recommend (for example 5–9Gy per fraction, 3–5
fractions). Despite the use of lower fractional doses, the responses
observed herein are robust. This could reflect the combinatorial
use of mEHT. However, it is also worth considering that other
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FIGURE 3 | Representative patient (Case 3) with autoimmune mediated abscopal effects: metastatic cholangiocarcinoma with abscopal tumor effect on L5 bony
metastases and change of CA-199 level.
clinical reports, such as the one by Chandra et al., demonstrated
that radiation fraction size <3Gy was the only parameter
identified to be associated with favorable index lesion response in
a cohort of melanoma patients treated with immune checkpoint
inhibitors and radiotherapy (20).
As the use of immunotherapy becomes more popular, irAE
is emerging as an issue (35). irAEs from ICP inhibitors are
generally regarded as a “toxicity,” however, a number of reports
are beginning to appear in the literature claiming that patients
with higher irAEs may have a higher response rate (36, 37).
In addition, patients with irAE have longer treatment durations
and more time to develop autoimmune toxicities (35). Clearly,
immunotoxicity and autoimmunity is a balancing act. In our
study, three out of 33 patients (9.1%) had induced autoimmune
reactions from RT + mEHT. They all had a profound abscopal
effect (>90% shrinkage of non-irradiated tumor, lasting for
more than 12 months) without any substantial systemic targeted,
cytotoxic, or ICP inhibitor therapy when autoimmune toxicities
were noted. Most abscopal effects reported in the literature are
neither “deep” (i.e., >90% tumor reduction), nor durable. For
example, in the series by Golden et al. (23), only two of 41 patients
(4.9%) had a dramatic abscopal response according to the criteria
of >90% tumor reduction. Therefore, we argue that the effective
immunity may be coupled to autoimmunity.
This case series of combining mEHT and RT for palliative
purposes demonstrated unexpected autoimmune toxicities along
with dramatic and sustained tumor regression. Despite being
interesting and inspiring, these results must be interpreted
with great caution and at best provide initial observations for
hypothesis-generation, as there are considerable limitations given
the retrospective, single institution analysis, with limited patient
numbers, and considerable heterogeneity. An official prospective
trial combining immune check point inhibitors with RT and
mEHT will be launched.
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